Parse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products Parse Biosciences, a leading innovator in scalable and accessible single-cell sequencing technology, has reaffirmed its commitment to advancing its Evercode™ single-cell…
Repligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million Repligen Corporation (Nasdaq: RGEN), a leading life sciences company specializing in bioprocessing technology, has announced the acquisition of 908 Devices…
Shorla Oncology Expands U.S. Presence with New Sales & Market Access Teams Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, has officially launched a dedicated sales force and market access…
Medable Secures CNIL Approval, Paving the Way for Digital Clinical Trials in the EU Medable Inc., a global leader in clinical development technology, has reached a significant regulatory milestone with…
NationsBenefits® Reinforces Nutrition-First Approach to GLP-1 Support During National Nutrition Month As National Nutrition Month brings attention to the critical role of healthy eating in disease prevention and overall wellness,…
FDA Grants Orphan & Rare Pediatric Status to NEU-001 for Hirschsprung Disease Neurenati Therapeutics Inc., a biotechnology company specializing in rare pediatric diseases, has announced a significant regulatory milestone. The…
Amylyx Reports Q4 and Full-Year 2024 Financial Results Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) recently released its financial results for the fourth quarter and full year ending…
TEVIMBRA Gains U.S. Approval for First-Line Esophageal Cancer Treatment with Chemotherapy BeiGene, Ltd. a global oncology company that has announced its intent to change its name to BeOne Medicines Ltd.,…
Centauri Therapeutics Advances Lead Immunotherapy for Gram-Negative Infections Centauri Therapeutics Limited (Centauri), a pioneering immunotherapy company with a proprietary platform technology applicable across multiple therapeutic areas, has announced the selection…
FairJourney Biologics Acquires Charles River’s South San Francisco Site FairJourney Biologics S.A., a global leader in antibody discovery and optimization, has announced the successful acquisition of the South San Francisco…
Osivax Secures Key Funding to Advance Next-Gen Influenza Vaccines Osivax, a biopharmaceutical company dedicated to developing next-generation vaccines that offer broad-spectrum protection against highly mutating respiratory viruses, has successfully secured…
Gensaic Partners with Novo Nordisk to Advance Next-Gen Precision Therapies Gensaic, Inc., a pioneering biotechnology company leveraging AI-driven protein design and biological insights to develop precision ligands for targeted drug…